Best Life Sciences Platforms and Tools Companies in Belgium
The 82 best Life Sciences Platforms and Tools companies in Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Univercells.
- ResearchAndMarkets.com
- Precedence Research
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Belgium
| # | Company | Disclosed funding | Employees | Founded | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Univercells Provider of biomanufacturing technology services for biopharma sector | $151M | 88 | 2013 | Jose Castillo Co-Founder & CTO | WordPressZohoMySQL+25 | Top 50M | 74 patents Biomanufacturing platforms for cell culture, protein purification, and viral vaccine production | — |
| 2 | Novadip Developer of stem cell-based therapies for bone healing disorders and bone defects | $77M | 39 39 → 58 (+49%) | 2013 | — | WordPressMySQLPHP+16 | Top 50M | — | — |
| 3 | OncoDNA Theranostic and genomic company for precision medicine in oncology | $45M | 37 37 → 46 (+24%) | 2012 | — | Cart FunctionalityWordPressApple iCloud Mail+38 | Top 5M | 35 patents Personalized cancer neoantigen vaccines and tumor sequencing for individualized immunotherapy | — |
| 4 | reMYND Developer of a drug pipeline programs for neurodegenerative diseases | $29M | 46 46 → 28 (-39%) | 2002 | Joris Winderickx Co-Founder And Sab Member | — | — | 160 patents Small‑molecule therapeutics targeting neurodegenerative CNS disorders (aza‑spiroheptane, triazole, septin‑6 modulators). | — |
| 5 | Complix Developer of protein based therapeutics using proprietary alpha-body technology | $24M | 13 | 2008 | Mark Vaeck CEO | WordPressMySQLPHP+20 | Top 50M | 76 patents Engineered alphabody peptides for targeted protein binding, degradation, and antiviral delivery | — |
| 6 | Syndesi Therapeutics Developer of small molecule for treating Alzheimer's disease | $21M | 1 | 2018 | — | — | — | 14 patents Small‑molecule triazol derivatives for treating cognitive (neurodegenerative) disorders | — |
| 7 | EXO Biologics Developer of cell-based therapeutics | $17M | 21 | 2019 | — | Windows ServerBootstrapStimulus+10 | Top 50M | 25 patents Manufacturing protein‑associated extracellular vesicles for cell‑derived therapeutic applications | — |
| 8 | Bio Base Europe Pilot Plant Provider of biobased product process development, scale-up, and custom manufacturing | $15M | 146 146 → 178 (+22%) | 2008 | Wim Soetaert CEO | Tailwind CSSGSAPVue.js+20 | Top 10M | — | — |
| 9 | Trinean UV/VIS spectrometry solutions | $9M | 19 | 2006 | — | — | — | 42 patents Quantitative optical analysis of DNA/RNA and multi-angle DLS using microfluidic platforms | — |
| 10 | Ovizio Developer of an imaging system for microscopes | $9M | 16 | 2009 | — | — | — | — | — |
| 11 | Diagenode Developer of portfolio of reagents and kits for epigenetics sequencing solutions | $8M | 99 99 → 125 (+26%) | 2003 | — | Cart FunctionalityPHPSalesforce+28 | Top 5M | 39 patents Patents concentrated in chemistry & materials | — |
| 12 | Pharma Diagnostics Absorption plate-based LSPR assay for analyzing biomolecular interactions | $7M | 8 | 2007 | Pierre Saelen CEO | — | — | — | — |
| 13 | FOx Biosystems Developer of fiber optic bio-sensing technology based on surface plasmon resonance | $5M | 9 | 2017 | Filip Delport Co-Founder & CEO | — | — | 18 patents Thin‑film sputter deposition equipment and fiber‑optic sensor/connector technologies | — |
| 14 | Trince Developer of cell transfection machinery | $5M | 3 | 2019 | Kevin Braeckmans Co-founder and CSO/CTO | WordPressMySQLPHP+19 | Top 50M | — | — |
| 15 | Pepric In vivo imaging using magnetic nanoparticles. | $3M | 2 | 2009 | — | — | — | 21 patents Quantitative magnetic particle analysis using electron paramagnetic resonance techniques | — |
| 16 | RheaVita Developer of an instrument for continuous freeze drying | $3M | 4 | 2018 | Jos Corver Co-Founder | HubSpot CMS HubHubSpot ChatMicrosoft 365+12 | Top 50M | 20 patents Advanced freeze‑drying and controlled freezing/thawing equipment for liquid mixtures | — |
| 17 | Formac Pharma Drug delivery solutions for poorly soluble APIs | $2M | 3 | 2007 | Laurens Theunis Co-Founder | — | — | — | — |
| 18 | Molecubes Developer of solutions for preclinical benchtop imaging | $2M | 16 | 2014 | Ewout Vansteenkiste Co Founder - Board of Directors | WordPressAlgoliaMySQL+23 | Top 50M | 10 patents Veterinary heating pads and stationary SPECT imaging with crystal detector calibration | — |
| 19 | ImmuneSpec Developer of sensitive MHC associated peptide proteomics for researchers | $1M | 3 | 2023 | Kurt Boonen Chief Data Officer - Co-Founder | — | — | — | — |
| 20 | Delphi Genetics Provider of research services in molecular biology, protein engineering, and antibody development | $1M | 85 | 2001 | — | — | — | 26 patents Engineered bacterial hosts and modified bacteriophages for recombinant protein/biomolecule production | — |
| 21 | Cell Matters CDMO focused on manufacturing of cell therapy products | $872K | 6 | 2017 | Delphine Connan Co-Founder | — | — | 10 patents Formulating cryopreservation solutions for preserving biological materials | — |
| 22 | Memobead Technologies Technology solution for in vitro diagnostics and forensics | $720K | — | 2003 | Stefaan De Smedt Founder | — | — | — | — |
| 23 | SEPS Pharma Pharma company developing prodrug approaches and drug delivery systems | $707K | 9 | 2007 | Yves Gonnissen Co-Founder & Managing Director | — | — | — | — |
| 24 | SynAbs Developer of monoclonal antibody platform against poor immunogenic compounds | $632K | 8 | 2015 | Yannick Nizet Co-Founder & CSO | JimdoAnimate.cssMustache+11 | Top 50M | 2 patents Therapeutic anti‑CCR8 antibodies for immunomodulation and disease treatment | — |
| 25 | ATLAS Neuroengineering Silicon based probes | $615K | — | 2012 | Arno Aarts Co-Founder & CEO | Microsoft ASP.NETBootstrapFancyBox+5 | Top 50M | 6 patents Implantable neural probes and hyperdrive systems for precise brain stimulation and recording | — |
| 26 | Bio INX Provider of diverse 3D printing inks | $501K | — | 2022 | Agnes Dobos Co-Founder | Cart FunctionalityDrupalPHP+12 | Top 10M | — | 2 partnerships |
| 27 | StratiCELL Integrated solution provider for in vitro testing of skin care and dermatology products | $440K | 11 | 2005 | Michel Salmon CEO | — | — | — | — |
| 28 | Progenus Provider of DNA analysis services and diagnostic kits | $395K | 14 14 → 14 (+0%) | 2001 | Robert Renaville Co-Founder & CEO | — | — | — | 3 launchs |
| 29 | Targetome Developing ADC (antibody-drug conjugates) for the treatment of cancer such as pancreatic cancer. | $393K | — | 2010 | Christophe Van Huffel ex-CEO | — | — | — | — |
| 30 | DNAVision Provider of a wide range of genomic services to the pharmaceutical, food, and biotechnology industries | $294K | 5 | 2004 | Laurent Alexandre CEO | — | — | — | — |
| 31 | The Cell Factory Provides of-the-shelf advanced biologics and autologous stem cells | $187K | — | 2002 | Frederic Amar CEO | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Belgium
#1
Series B · Mont Saint Guibert, Wallonia · founded 2013 · 39 employees$77Mraised▾
Developer of stem cell-based therapies for bone healing disorders and bone defects. The company has developed regenerative therapeutics which include NVD-X3 for hard tissue reconstruction and NVD-X2 for soft tissue reconstruction. The m3 platform technology creost is a 3D osteogenic structure from autologous adipose-derived stem cells which reconstruct critical size bone defects without the use of any scaffold.
- Dec 2023Venture Debt$19.7M
- Nov 2022Grant (prize money)$15.8M
- Nov 2022Series B$23.7M
- Oct 2021Series B$22M
#2
Series A · Niel, Flanders · founded 2019 · 21 employees$17.1Mraised▾
Developer of cell-based therapeutics. The company is developing extracellular vesicles and exosome drugs that can replace stem cell therapies. These extracellular vesicles are developed from mesenchymal stem cells. Extracellular vesicles function includes intracellular communication, transfer of proteins, lipids, and genetic material. These drugs are developed for inflammatory diseases, autoimmune diseases, and acute tissue injuries. These vesicles can also be used as a carrier for drug substances as they can transmit molecules between the cells and tissues.
- Apr 2024Series A$17.1M
#3
Series C · Charleroi, Wallonia · founded 2012 · 37 employees$44.5Mraised▾
Theranostic and genomic company for precision medicine in oncology. The company's biomarker tests include OncoDEEP for precision medicine, OncoSELECT is a liquid biopsy solution for monitoring and therapeutics, and OncoFOLLOW is to monitor the progression of the tumor. Also has NGS interpretation platform OncoKDM for clinical information and biomarker test platform OncoSHARE.
#4
Series D · Charleroi, Wallonia · founded 2013 · 88 employees$150.6Mraised▾
Univercells technologies have developed instrument systems for the production of antibodies, proteins, and vaccines. The company's proprietary technology includes scale-x bioreactor and nevoline platform. Scale-x bioreactor provides upstream processing of viral products which can help to deliver viral vaccines and gene therapies.
- Oct 2022Series D$43.3M
- Dec 2020Series C$85.2M
- Feb 2020Series C—
- Oct 2019Conventional Debt$21.9M
#5
Funding Raised · Gembloux, Wallonia · founded 2001 · 14 employees$395Kraised▾
Provider of research and laboratory services intended to test animal genetics. The company's departments develop and sell their own analysis kits, provide services like DNA analysis, and help in the research and development of a simple test to a complete project, enabling businesses to perform tests on animals, plants and microorganisms.
- Jan 2024Grant (prize money)$395K
#6
Series A · Temse, Flanders · founded 2017 · 9 employees$4.5Mraised▾
FOx Biosystems is a spin-off from the MeBioS Biosensor group of the KU Leuven. They have developed a fiber optic biosensing technology based on surface plasmon resonance. Their proprietary SPR technology offers biomolecular interaction analyses. The instrument, White Fox 1.0 is used for the quantification of specific proteins, small molecules, cellular bioreactor development, and DNA or cells in microliter volumes.
- Dec 2022Grant (prize money)$2.8M
- Mar 2021Grant (prize money)$308.7K
- Feb 2019Series A$4.5M
#7
Funding Raised · Gentbrugge, Flanders · founded 2008 · 146 employees$15.1Mraised▾
Provider of biobased product process development, scale-up, and custom manufacturing. It offers services from laboratory to multi-ton scales, translating lab protocols into viable industrial processes. The company utilizes technologies such as biomass pretreatment, biocatalysis, fermentation, green chemistry, and product purification. It supports bilateral and consortium-based projects, along with technology development initiatives. The firm also provides engineering services and public project support.
- Jun 2021Grant (prize money)$928.4K
- May 2021Grant (prize money)$1.3M
- Mar 2021Grant (prize money)$526.9K
- Jan 2021Grant (prize money)$730.5K
#8
Series B · Leuven, Flemish Region · founded 2002 · 46 employees$29.1Mraised▾
reMYND is a CRO that is also developing a drug pipeline for neurodegenerative diseases. The company provides in vivo contract research services based on its proprietary mouse models: progressive amyloid-o-pathy (APP), progressive tau-o-pathy (TAU) and an APP + TAU model. Its drug discovery program is focused on small molecule therapeutics for neurodegenerative diseases, specifically those caused by protein-misfolding. Its lead candidate is completing IND-enabling studies for Alzheimer's disease. In company has three other candidates for Alzheimer's disease, two for diabetes, two for Parkinson's disease, and one candidate each for Huntington's disease and amyloid lateral sclerosis.
- Jan 2021Series B$14.6M
- Dec 2018Series B$13.6M
- Mar 2016Grant (prize money)$524.8K
- Jun 2011Grant (prize money)$2.1M
#9
Seed · Hove, Antwerp Province · founded 2023 · 3 employees$1.3Mraised▾
Developer of sensitive MHC associated peptide proteomics for researchers. The company offers an immunopeptidomics as a service, which is Mass Spectrometry based MHC associated peptide identification for life science companies, biotech companies, and CRO's in the development of broad-spectrum vaccines, personalized medicine, and immunotherapeutics.
- Mar 2023Seed$1.3M
#10
Public · Leuven, Flemish Region · founded 2012$614.5Kraised▾
ATLAS Neuroengineering is a spin-off company of imec, Leuven and IMTEK, University of Freiburg, established with the technology developed under European FP6 program “NeuroProbes”. The product portfolio includes a wide range of silicon-based probes comprising typically 8 to 64 electrodes per probe and electronic depth control (EDC) probes. The company is specialized in silicon microfabrication, system integration, biocompatibility, and histology. It offers tools and solutions for the experimental neuroscience to record and stimulate neuronal activity. In addition, it offers high-density, silicon-based neural probes for application in cortical and thalamic brain applications as well as for intraspinal microstimulation (ISMS).
- Mar 2023Grant (prize money)$192K
- Mar 2021Grant (prize money)$308.7K
- Jan 2021Grant (prize money)$113.9K
#11
Series B · Diepenbeek, Flanders · founded 2008 · 13 employees$24.4Mraised▾
Complix is involved in developing alpha-bodies (protein therapeutics) for treating cancer and autoimmune diseases. The company uses its propriety Alpha-bodies to combine their target specificity and affinity with small chemical drugs capability to penetrate cell membranes. The company leading candidate CMX-02 is used in the treatment for severe autoimmune disease and alpha-bodies are active in a variety of tumor cells whilst non-toxic to normal human cells.
- Dec 2017Grant (prize money)$588.3K
- Mar 2015Grant (prize money)$279.6K
- Jun 2013Series B$15.5M
- Oct 2012Grant (prize money)$2.5M
#12
Series A · Ghent, Flanders · founded 2019 · 3 employees$4.5Mraised▾
Developer of cell transfection machinery. The company has developed a proprietary LumiPore platform for efficient cytosolic delivery of various compounds, including nucleic acids, proteins, contrast agents. The technology is applicable to transfect a broad range of cell types, such as stem cells and immune cells.
- Dec 2021Series A$4.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Belgium
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 628 Belgium-affiliated papers.
- Triphase136
- KU Leuven110
- Ghent University80
- Ghent University Hospital57
- Université Libre de Bruxelles34
- Gene1→19
- Genome4→15
- Identification (biology)1→7
- Cancer1→6
- Immune system1→6
- Disease1→21
- Cancer1→18
- Epigenetics1→8
- microRNA1→6
- Gut microbiome2→4
- Disease2→34
- Immune system1→13
- Inflammation1→6
- Genome2→6
- Gut microbiome1→4
Where bioinformatics is researched across Belgium
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.